Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors

Heudel, Pierre; Cimarelli, Sébastien; Montella, A.; Bouteille, C.; Mognetti, Thomas

doi:10.1007/s10147-010-0120-3

Cited by 68 publications

(61 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have demonstrated a relationship between SUV and hormone receptors such as ER [16,21] and PR [21]. We found lower SUVmax1 and SUVmax2 in ER-and PR-positive patients.…”

Section: Suvmax Of the Primary Lesionsupporting

confidence: 45%

“…In a study performed by Heudel et al [21], the low SUVmax level in T1 tumors was thought to be related to a partial volume effect. Our study did not include T1a-T1b tumor sizes to avoid partial volume effects in our results.…”

Section: Suvmax Of the Primary Lesionmentioning

confidence: 99%

“…The 18 F-FDG uptake of the primary tumor in various publications has been found to be positively related to tumor size [16][17][18]21], whereas other studies revealed that there was no relationship [15,20]. In a study performed by Heudel et al [21], the low SUVmax level in T1 tumors was thought to be related to a partial volume effect.…”

Section: Suvmax Of the Primary Lesionmentioning

confidence: 99%

See 2 more Smart Citations

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

et al. 2016

View full text Add to dashboard Cite

The aims of this retrospective study were to consider the diagnostic role of dual-time 18 F-fluorodeoxyglucose positron emission tomography and computed tomography ( 18 F-FDG PET/CT) in detection of breast carcinoma and axillary lymph node (ALN) status and to evaluate the primary tumor 18 F-FDG uptake pattern. Preoperative staging was performed by 18 F-FDG PET/CT in 78 female patients with breast carcinoma. Conventional imaging results were evaluated by breast magnetic resonance imaging (MRI) of 79 lesions in 78 patients, bilateral mammography (MMG) of 40 lesions in 40 patients, and breast ultrasonography (USG) of 47 lesions in 46 patients. The primary tumor detection rate using 18 F-FDG PET/CT was higher than those using MRI, USG, and MMG. The sensitivity and specificity of 18 F-FDG PET/CT scans for detecting multifocality were higher than those of MRI. The specificity of ALN metastasis detection with MRI was higher than that with 18 F-FDG PET/CT, but 18 F-FDG PET/CT had higher sensitivity. Higher 18 F-FDG uptake levels were detected in patients with ALN metastasis, histologic grade 3, estrogen-progesterone-negative receptor status, lymphatic invasion, and moderate to poor prognostic groups. There was no statistical difference for the retention index in categorical pathological parameters except for progesterone-negative status.In conclusion, 18 F-FDG PET/CT scans may be a valuable imaging technique for evaluating primary tumor and axillary status in staging breast carcinoma and 18 F-FDG uptake may be a prognostic factor that indicates aggressive tumor biology and poor prognosis. Dual-time imaging in breast carcinoma staging may not be used for predicting pathological criteria and the aggressiveness of primary lesions.

show abstract

“…Some studies have demonstrated a relationship between SUV and hormone receptors such as ER [16,21] and PR [21]. We found lower SUVmax1 and SUVmax2 in ER-and PR-positive patients.…”

Section: Suvmax Of the Primary Lesionsupporting

confidence: 45%

Section: Suvmax Of the Primary Lesionmentioning

confidence: 99%

Section: Suvmax Of the Primary Lesionmentioning

confidence: 99%

See 1 more Smart Citation

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Conflicting results have been reported as the correlation between FDG uptake and PR status. Some studies have claimed higher SUVmax in the PR (−) breast cancer [39,40], but other reports showed no association between PR status and FDG uptake [41,42]. Ekmekcioglu et al [42] suggested that the cut-off level of the PR limit of positivity might be relevant to the result.…”

Section: Discussionmentioning

confidence: 99%

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

Moon

Noh

Kim

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose This study investigates the correlation of retention index (RI) using the dual phase FDG PET/CT scan with the breast cancer biomarkers. Methods A total of 55 patients with breast cancer underwent dual phase FDG PET/CT scans (60 and 120 min after FDG injection) before treatment. SUVmax and SUVmean of the primary breast tumors were measured, then the percent change of SUVmax and SUVmean between the two scans were calculated, and denoted as RImax and RImean, respectively. After the surgical resection of the breast tumor, the status of biomarkers (ER, PR, and HER-2) was evaluated in the postsurgical specimen.

show abstract

“…Many groups have demonstrated good correlations between primary tumor FDG uptake on PET/CT, expressed as the maximum standardized uptake value (SUV max ), and clinicopathological findings that are known to be important prognostic indicators in breast cancer patients [10][11][12][13][14][15][16][17]. A higher SUV max is reported to be significantly associated with estrogen receptor (ER) negativity, progesterone receptor (PR) negativity, human epidermal growth factor receptor 2 (HER2) positivity, a high Ki-67 index, a bigger tumor size, a higher histological grade, presence of axillary lymph node (LN) metastasis, and a higher stage.…”

Section: Factors Correlated With Fdg Uptake In Primary Breast Tumorsmentioning

confidence: 99%

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Kitajima

Miyoshi

2016

Jpn J Radiol

View full text Add to dashboard Cite

by malignant cells, opened a new field in clinical oncologic imaging. Recently, integrated positron emission tomography/computed tomography (PET/CT), in which a full-ringdetector clinical PET scanner and multidetector-row helical CT scanner are combined, has made it possible to acquire both metabolic and anatomic imaging data using a single device in a single diagnostic session, and provides precise anatomic localization of suspicious areas of increased FDG uptake. When used in a clinical setting, FDG-PET/CT leads to a significant improvement in diagnostic accuracy and has had a considerable impact on patient management, including diagnosis, initial staging, optimization of treatment, restaging, monitoring of the response to therapy, and prognostication of various malignant tumors. We herein review the current and future roles of FDG-PET/CT in the management of breast cancer, discussing its usefulness and limitations for imaging in these patients. DiagnosisFDG-PET imaging has poor sensitivity (<50 %) for subcentimeter breast cancers [9,10]. This is due to the limited spatial resolution of PET and, in some cases, by tumor characteristics (e.g., low FDG avidity in grade 1 cancer, ductal carcinoma in situ, or lobular carcinoma) [1,2]. Specificity can also be altered by variations of FDG uptake in certain benign conditions, such as infection, fibroadenoma, ductal adenoma, inflammatory granulomatous mastitis, and fibrocystic changes [3].In order to improve specificity, some authors would obtain a second series of PET images centered on the breast approximately 2 h after FDG injection (dual-time imaging) [4]. Indeed, FDG uptake seems to increase with time in the case of malignancy, while some inflammatory lesions show stable or decreasing uptake [4]. However, dual-time Abstract Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxyd-glucose (FDG) is a useful tool for acquisition of both glucose metabolic and anatomic imaging data using a single device in a single diagnostic session, and has opened a new field in clinical oncologic imaging. FDG-PET/CT has been used successfully for the diagnosis, initial staging, restaging, early treatment response assessment, evaluation of metastatic disease response, and prognostication of breast cancer as well as various malignant tumors. We herein review the current place and role of FDG-PET/CT in the management of breast cancer, focusing on its usefulness and limitations in the imaging of these patients.

show abstract

Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors

Cited by 68 publications

References 24 publications

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Contact Info

Product

Resources

About